Compound polysaccharide for regulating and controlling immune balance of Th1 / Th2 as well as preparation method and application of compound polysaccharide
Through the composite preparation of plant polysaccharides such as Agaricus, seaweed, licorice, and polysaccharide, the problems of Th1/Th2 immune balance regulation and ovalbumin caused immune stress were solved, and the significant immune regulation effect with non-toxic side effects and allergic symptoms were achieved.
Patent Information
- Application Number
- CN202411262831.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-09
- Publication Date
- 2024-12-06
AI Technical Summary
The prior art is difficult to effectively regulate Th1/Th2 immune balance, especially in the immune stress response caused by ovalbumin, which leads to allergies and the immune regulation effect of a single plant polysaccharide is limited.
Complex polysaccharides are prepared by mixing Agaricus, seaweed, licorice, polysaccharide and honeysuckle in a specific proportion. Polysaccharide compositions are obtained through extraction and alcohol precipitation to regulate Th1/Th2 immune balance, and prevent and inhibit the immune stress response caused by ovalbumin.
The complex polysaccharides that are consumed for a long time have no obvious toxic side effects, and significantly enhance the immune regulation effect. They are better than single polysaccharides. They can regulate Th1/Th2 immune balance, prevent and inhibit the immune stress response caused by ovalbumin, and provide egg clearance. Effective support for the widespread use of proteins.
Smart Images

Figure BDA0005036678500000081 
Figure BDA0005036678500000091 
Figure BDA0005036678500000121
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of biomedicine, and specifically relates to a composite polysaccharide for regulating Th1 / Th2 immune balance, and a preparation method and application thereof. Background Art
[0002] There are two kinds of immune cell balance in animals, namely Th1 / Th2 immune cell balance. They complement each other in the immune process in the body, but also have a mutually inhibitory effect on each other, so that cellular immunity and humoral immunity are in a balanced state. Generally, Th1 mediates cellular immune response in the body. They directly attack pathogens or promote other cells to attack pathogens. Even if pathogens enter infected cells, they will still attack. Th2 mainly mediates humoral immune response. Th2 cells will not enter infected cells. They will promote other immune cells to produce antibodies. For example, IL-13 and IL31 are one of their signature antibodies. These antibodies attack foreign substances. Th1 / Th2 imbalance will cause the body to produce different immune diseases, such as rheumatoid arthritis, multiple sclerosis and other diseases, and when Th2 cells are strong, it will cause allergic diseases, asthma, dermatitis, etc.
[0003] The main proteins in egg white include ovalbumin, ovotransferrin, ovoglobulin, ovoglobulin, lysozyme, globulin G2, globulin G3, etc. Ovalbumin is the main protein component in egg white. It is a phosphoglycoprotein, accounting for 54%-69% of the total protein in egg white. It is the most important protein in egg white. It is composed of 386 amino acid residues, with a relative molecular mass of about 45,000 and an isoelectric point of 4.5.
[0004] Ovalbumin has many uses. For example, it is a component that can enhance human immunity. The humoral immunity and cellular immunity of the human body are composed of proteins, so the immune function can be improved by supplementing ovalbumin. At the same time, ovalbumin can not only increase the water retention capacity of the skin and improve the moisturizing effect, but also adjust the surface oil of the skin to an appropriate amount, so that the tissues in the skin are more tightly bound. Ovalbumin has rich nutritional value and good functional properties, and can be used in food processing. For example, it has a strong emulsifying effect and can be used as an emulsifier in food processing. At the same time, ovalbumin has good interfacial adsorption ability and can form gels for processing in the food industry. Due to the safe source of ovalbumin, excellent foaming, hydrophilicity, emulsification and easy gelation, it is also widely used in baby food, meat processing, bread and dessert manufacturing. Recently, ovalbumin has also been widely used in the research of drug and vaccine preparations, such as ovalbumin liposome transdermal vaccines, nanoparticle antibacterial agents, nanolipid carriers, microsphere pulse sustained release systems, nanoparticle nasal delivery systems, etc.
[0005] Although ovalbumin has a very wide range of applications, it is one of the main allergens in egg white. At present, in order to reduce its immune stress response, most of them are modified by glycosylation and enzymatic hydrolysis to obtain low-allergenic ovalbumin. However, some people are still prone to immune stress response after using foods and preparations containing ovalbumin and its modified proteins, which manifests as allergic phenomena. In response to its allergic phenomenon, most of them currently use chemical drugs to antagonize, including loratadine, cetirizine hydrochloride, calamine lotion, hydrocortisone cream, etc. However, they all have certain side effects, such as dry mouth, headache, occasional abnormal liver function, and even systemic allergic reactions in severe cases.
[0006] In recent years, many studies have shown that plant polysaccharides (including edible fungus polysaccharides) have a good regulatory effect on the body's immunity, and have gradually been used in clinical treatment or improvement of the body's immune status. However, the efficacy of this single plant polysaccharide under general application conditions is often very limited.
[0007] In this regard, patent CN101518556A discloses a polysaccharide composition that enhances humoral and cellular immune responses of ovalbumin-immunized mice, which can induce immune responses and enhance mouse immunity. In addition, patent CN109463742A discloses a polysaccharide formula and its preparation process that can enhance human immunity, which can also achieve the effect of enhancing human immunity. However, at present, how to deal with the immune stress state brought about by ovalbumin as an immunity-enhancing adjuvant and how to deal with the allergic phenomena induced by it are still lacking in the field of polysaccharide immunoregulation. Summary of the invention
[0008] The object of the present invention is to provide a composite polysaccharide which can adjust the Th1 / Th2 immune balance and prevent and / or inhibit the immune stress response caused by ovalbumin.
[0009] The technical solution adopted by the present invention is:
[0010] The first aspect of the present invention provides a polysaccharide composition, comprising a polysaccharide extract of a raw material drug, wherein the raw material drug comprises Agaricus blazei, seaweed, liquorice, polygonatum and honeysuckle.
[0011] In some embodiments of the present invention, the raw materials include, by mass percentage: 20%-40% Agaricus blazei, 10%-30% seaweed, 5%-25% liquorice, 5%-25% polygonatum, and 5%-20% honeysuckle.
[0012] In some embodiments of the present invention, the raw materials include, by mass percentage: 30%-40% Agaricus blazei, 10%-20% seaweed, 10%-25% liquorice, 15%-25% polygonatum, and 5%-15% honeysuckle.
[0013] In some embodiments of the present invention, the raw materials include, by mass percentage: 20%-40% Agaricus blazei, 10%-16% seaweed, 22%-25% liquorice, 20%-25% polygonatum, and 5%-20% honeysuckle.
[0014] In some embodiments of the present invention, the raw materials include, by mass percentage: 20%-30% Agaricus blazei, 10%-16% seaweed, 22%-25% liquorice, 20%-22% polygonatum, and 5%-10% honeysuckle.
[0015] In some embodiments of the present invention, the seaweed is at least one of brown algae (Phaeophyta), red algae (Rhodophyta), kelp (Laminaria japonica), and wakame (Undaria pinnatifida Suringar).
[0016] In some embodiments of the present invention, the licorice is at least one of Glycyrrhiza uralensis Fisch., Glycyrrhiza inflata Batal., and Glycyrrhiza glabra L.
[0017] In some embodiments of the present invention, the molecular weight of the polysaccharide composition is 0.5-2432 KDa.
[0018] In some embodiments of the present invention, the monosaccharide composition of the polysaccharide composition includes mannose, rhamnose, galactose, glucose, xylose, arabinose, fucose, and galacturonic acid.
[0019] In some embodiments of the present invention, the monosaccharide composition of the polysaccharide composition includes 0.5-1.5% mannose, 1-2% rhamnose, 0.2-0.6% galactose, 75-85% glucose, 12-14% xylose, 0.5-1.2% arabinose, 1.5-2.5% fucose, and 0.2-0.6% galacturonic acid.
[0020] In some embodiments of the present invention, the structure of the polysaccharide composition is a crystalline and amorphous mixed lamellar structure containing triple helices.
[0021] Agaricus blazei Murill, also known as Brazilian mushroom, is a fungus that can be used as both medicine and food. It belongs to the genus Agaricus (black umbrella) family, Agaricus (black umbrella) family, Agaricaceae, and is rich in protein and polysaccharides. Studies have shown that Agaricus blazei Murill polysaccharides have antiviral, antioxidant and immune regulation effects.
[0022] Seaweed contains a large amount of seaweed polysaccharides, which are high-molecular compounds composed of multiple identical or different monosaccharides connected by glycosidic bonds. Brown algae polysaccharides, fucoidan, red algae polysaccharides, etc. belong to this category; seaweed polysaccharides have good gelation, stability, and film-forming properties, and also have multiple biological activities such as antiviral, anticoagulant, anti-tumor, immunomodulatory, and antioxidant.
[0023] Licorice is a traditional Chinese herbal medicine with a long history. It is widely used in medicine, food and industrial production. Licorice contains polysaccharides, flavonoids and saponins. Licorice polysaccharide is the active polysaccharide extracted from it. It is easily soluble in water and shows therapeutic activity on diseases such as inflammation caused by infection. It also has anti-tumor, anti-viral, antioxidant and anti-inflammatory effects.
[0024] Polygonatum sibiricum is the dried rhizome of Polygonatum kingianum, P. sibiricum, or P. cyrtomema, all of which belong to the Liliaceae family. Modern research has shown that Polygonatum sibiricum polysaccharide is one of the main active ingredients in Polygonatum sibiricum, which has anti-tumor, antioxidant, anti-inflammatory and antibacterial effects, can regulate blood sugar and blood lipids, and has antiviral, immunity-enhancing and memory-improving effects.
[0025] Honeysuckle is the dried buds or initially opened flowers of the Caprifoliaceae plant Lonicera japonica Thumb. It is listed as a top-grade product in Shennong's Herbal Classic. It is cold in nature, sweet in taste, and has the effects of clearing away heat and detoxifying, cooling and dispersing wind-heat. The honeysuckle polysaccharides extracted from it have anti-tumor, antioxidant, antiviral, immunomodulatory, hypoglycemic and hypolipidemic effects.
[0026] The present invention finds that mixing Agaricus blazei, seaweed, liquorice, polygonatum and honeysuckle in the above proportion to prepare a composite polysaccharide can adjust the Th1 / Th2 balance and prevent and / or inhibit the immune stress response caused by ovalbumin.
[0027] The second aspect of the present invention provides a method for preparing the polysaccharide composition of the first aspect of the present invention, comprising the following steps: crushing the raw materials and mixing them, soaking and extracting them in water, collecting and concentrating the filtrate, precipitating them with alcohol, and collecting the precipitate.
[0028] In some embodiments of the present invention, the raw material is crushed to pass 20-100 mesh.
[0029] In some embodiments of the present invention, the material-liquid ratio of the raw material to water is 1:10-20 g / mL.
[0030] In some embodiments of the present invention, the soaking time is 20 to 40 minutes.
[0031] In some embodiments of the present invention, the extraction conditions are: temperature 70-90° C., time 2-4 h.
[0032] In some embodiments of the present invention, the extraction further includes filtering; specifically, filtering using a 200-400 mesh filter cloth.
[0033] In some embodiments of the present invention, the alcohol precipitation is performed by adding 3 to 5 times the volume of anhydrous ethanol and letting it stand for 10 to 14 hours.
[0034] The third aspect of the present invention provides the use of the polysaccharide composition described in the first aspect of the present invention in any of the following:
[0035] (1) Preparation of products for regulating Th1 / Th2 balance;
[0036] (2) preparing products for preventing and / or treating diseases related to Th1 / Th2 imbalance;
[0037] (3) Application in the preparation of products for improving immunity.
[0038] In some embodiments of the present invention, the Th1 / Th2 imbalance-related diseases include allergies and / or allergy-related diseases.
[0039] In some embodiments of the present invention, the allergy-related diseases include allergic rhinitis, allergic asthma, etc.
[0040] In some embodiments of the present invention, the body allergy includes but is not limited to body allergy caused by ovalbumin.
[0041] In some embodiments of the present invention, the product further comprises excipients acceptable to food, medicine, and health care products.
[0042] The fourth aspect of the present invention provides a product, wherein the product comprises the polysaccharide composition described in the first aspect of the present invention.
[0043] In some embodiments of the present invention, the product includes at least one of food, medicine and health care product.
[0044] In some embodiments of the present invention, the function of the product is to regulate Th1 / Th2 balance or prevent and / or treat diseases related to Th1 / Th2 imbalance and / or improve immunity.
[0045] The polysaccharide composition can be prepared directly or by adding pharmaceutically acceptable excipients to any pharmaceutically acceptable dosage form. For example, oral preparations include capsules, tablets, powders, granules, teas or oral liquids. The drugs in the above dosage forms can be prepared according to conventional methods in the pharmaceutical field.
[0046] The fourth aspect of the present invention provides a method, comprising administering the composition of the first aspect of the present invention or the product of the third aspect of the present invention to a subject; the method is used for any of the following:
[0047] (1) Regulate Th1 / Th2 balance;
[0048] (2) Prevent and / or treat diseases related to Th1 / Th2 imbalance;
[0049] (3) Improve immunity.
[0050] In some embodiments of the present invention, the Th1 / Th2 imbalance-related disease includes allergy or allergy-related disease.
[0051] In some embodiments of the present invention, the allergy-related diseases include allergic rhinitis, allergic asthma, etc.
[0052] In some embodiments of the present invention, the allergy includes but is not limited to body allergy caused by ovalbumin.
[0053] In some embodiments of the present invention, the suitable daily dosage range of the composition is 1-500 mg / kg body weight; the above dosage can be administered in one dosage unit or divided into several dosage units, depending on the doctor's clinical experience and the dosage regimen including the use of other treatment methods.
[0054] In some embodiments of the present invention, when administered to animals, the daily dosage of the composition is 100 to 300 mg / kg / d, and / or the administration period is 2 to 4 weeks, and / or the administration method includes but is not limited to oral administration, direct oral administration, and injection.
[0055] "Subject" is defined herein to include animals, such as mammals, including but not limited to primates (eg, humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, and the like.
[0056] The beneficial effects of the present invention are:
[0057] The present invention provides a composite polysaccharide prepared from medicinal and edible plants and edible fungi as raw materials, wherein the raw materials include Agaricus blazei, seaweed, liquorice, polygonatum and honeysuckle; compared with the current drugs for treating immune stress induced by ovalbumin, the composite polysaccharide of the present invention can be eaten for a long time without obvious toxic side effects. Moreover, the composite polysaccharide of the present invention obtains a molecular weight segment that has an effect on immunoregulation after co-extraction, and has obvious synergistic benefits relative to the immunoregulatory effect of a single polysaccharide. The composite polysaccharide of the present invention can regulate the Th1 / Th2 immune balance, prevent and / or inhibit the immune stress response caused by ovalbumin, and provide effective support for the wide application of ovalbumin. BRIEF DESCRIPTION OF THE DRAWINGS
[0058] Figure 1 This is the molecular weight determination of the composite polysaccharide in Example 1.
[0059] Figure 2 This is a SEM scan of the complex polysaccharide in Example 1.
[0060] Figure 3 This is the Congo red test of the polysaccharide of Comparative Examples 1-5 and Example 1.
[0061] Figure 4 is the expression level of IL-13 and IL-31 in mouse serum; compared with the model group, *P<0.05, compared with the Example 1 group, #p<0.05.
[0062] Figure 5 is the expression level of IgE and HIS in mouse serum; compared with the model group, *P<0.05; compared with the Example 1 group, #p<0.05.
[0063] Figure 6 The rhinitis conditions of Example 1 are compared with those of Comparative Examples 1-5. DETAILED DESCRIPTION
[0064] The following will be combined with the embodiments to clearly and completely describe the concept of the present invention and the technical effects produced, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.
[0065] Example 1
[0066] A composite polysaccharide is prepared by mixing the following raw material components and mass percentages: 40% Agaricus blazei, 10% red algae, 25% Glycyrrhiza glabra, 20% Polygonatum sibiricum, and 5% Honeysuckle;
[0067] The polysaccharide is prepared by the following process: (1) the above raw materials are crushed separately and passed through a 45-mesh sieve for later use; (2) the raw material powders are mixed according to the percentage of the components of the composition, deionized water with a solid-liquid ratio of 1:15 (g / mL) is added, and the mixture is soaked for 30 minutes; (3) the material in step (2) is extracted at 80° C. for 3 hours, filtered through a 300-mesh filter cloth, and the filtrate is collected; (4) the filtrate in step (3) is concentrated at 70° C. to a viscous state, anhydrous ethanol is added in an amount of 4 times the volume of the viscous liquid, the polysaccharide precipitate is allowed to stand for 12 hours, and the polysaccharide precipitate is collected by filtration to obtain a composite polysaccharide.
[0068] Example 2
[0069] A composite polysaccharide is prepared by mixing the following raw material components and mass percentages: 20% Agaricus blazei, 10% brown algae, 25% Ural Glycyrrhiza uralensis, 25% Polygonatum sibiricum, and 20% honeysuckle;
[0070] The polysaccharide is prepared by the following process: (1) the above raw materials are crushed separately and passed through a 45-mesh sieve for later use; (2) the raw material powders are mixed according to the percentage of the components of the composition, deionized water with a solid-liquid ratio of 1:20 (g / mL) is added, and the mixture is soaked for 30 minutes; (3) the material of step (2) is extracted at 90° C. for 3 hours, filtered through a 300-mesh filter cloth, and the filtrate is collected; (4) the filtrate of step (3) is concentrated at 70° C. to a viscous state, anhydrous ethanol is added in an amount of 4 times the volume of the viscous liquid, the polysaccharide precipitate is allowed to stand for 12 hours, and the polysaccharide precipitate is collected by filtration to obtain a composite polysaccharide.
[0071] Example 3
[0072] A composite polysaccharide is prepared by mixing the following raw material components and mass percentages: 30% Agaricus blazei, 16% Undaria pinnatifida, 22% Glycyrrhiza uralensis, 22% Polygonatum sibiricum, and 10% Honeysuckle;
[0073] The polysaccharide is prepared by the following process: (1) the above raw materials are crushed separately and passed through a 45-mesh sieve for later use; (2) the raw material powders are mixed according to the percentage of the components of the composition, deionized water with a solid-liquid ratio of 1:10: (g / mL) is added, and the mixture is soaked for 30 minutes; (3) the material in step (2) is extracted at 70°C for 3 hours, filtered through a 300-mesh filter cloth, and the filtrate is collected; (4) the filtrate in step (3) is concentrated at 70°C to a viscous state, anhydrous ethanol is added in an amount of 4 times the volume of the viscous liquid, the polysaccharide precipitate is allowed to stand for 12 hours, and the polysaccharide precipitate is collected by filtration to obtain a composite polysaccharide.
[0074] Example 4
[0075] A composite polysaccharide is prepared by mixing the following raw material components and mass percentages: 40% Agaricus blazei, 30% Undaria pinnatifida, 10% Glycyrrhiza glabra, 5% Polygonatum sibiricum, and 15% Honeysuckle;
[0076] The polysaccharide is prepared by the following process: (1) the above raw materials are crushed separately and passed through a 45-mesh sieve for later use; (2) the raw material powders are mixed according to the percentage of the components of the composition, deionized water with a solid-liquid ratio of 1:10 (g / mL) is added, and the mixture is soaked for 30 minutes; (3) the material in step (2) is extracted at 70° C. for 3 hours, filtered through a 300-mesh filter cloth, and the filtrate is collected; (4) the filtrate in step (3) is concentrated at 70° C. to a viscous state, anhydrous ethanol is added in an amount of 4 times the volume of the viscous liquid, the polysaccharide precipitate is allowed to stand for 12 hours, and the polysaccharide precipitate is collected by filtration to obtain a composite polysaccharide.
[0077] Example 5
[0078] A composite polysaccharide is prepared by mixing the following raw material components and mass percentages: 40% Agaricus blazei, 20% Laminaria japonica, 5% Glycyrrhiza glabra, 15% Polygonatum sibiricum, and 20% Honeysuckle;
[0079] The polysaccharide is prepared by the following process: (1) the above raw materials are crushed separately and passed through a 45-mesh sieve for later use; (2) the raw material powders are mixed according to the percentage of the components of the composition, deionized water with a solid-liquid ratio of 1:10 (g / mL) is added, and the mixture is soaked for 30 minutes; (3) the material in step (2) is extracted at 70° C. for 3 hours, filtered through a 300-mesh filter cloth, and the filtrate is collected; (4) the filtrate in step (3) is concentrated at 70° C. to a viscous state, anhydrous ethanol is added in an amount of 4 times the volume of the viscous liquid, the polysaccharide precipitate is allowed to stand for 12 hours, and the polysaccharide precipitate is collected by filtration to obtain a composite polysaccharide.
[0080] Comparative Example 1
[0081] Glycyrrhiza glabra polysaccharide is prepared from Glycyrrhiza glabra by the following process: (1) Glycyrrhiza glabra raw material is crushed and passed through a 45-mesh sieve for later use; (2) the raw material powder is added with deionized water with a solid-liquid ratio of 1:15 (g / mL) and soaked for 30 minutes; (3) the material in step (2) is extracted at 80°C for 3 hours, filtered through a 300-mesh filter cloth, and the filtrate is collected; (4) the filtrate in step (3) is concentrated at 70°C to a viscous state, 4 times the volume of anhydrous ethanol is added according to the volume of the viscous liquid, the alcohol precipitation is allowed to stand for 12 hours, and the polysaccharide precipitate is filtered and collected to obtain the polysaccharide component of Glycyrrhiza glabra extract.
[0082] Comparative Example 2
[0083] The polysaccharide of Agaricus blazei was prepared by the following process: (1) Agaricus blazei raw material was crushed and passed through a 45-mesh sieve for later use; (2) the raw material powder was added into deionized water with a solid-liquid ratio of 1:15 (g / mL), and soaked for 30 minutes; (3) the material of step (2) was extracted at 80°C for 3 hours, filtered through a 300-mesh filter cloth, and the filtrate was collected; (4) the filtrate of step (3) was concentrated at 70°C to a viscous state, 4 times the volume of anhydrous ethanol was added according to the volume of the viscous liquid, and the alcohol precipitation was allowed to stand for 12 hours, and the polysaccharide precipitate was collected by filtration to obtain the polysaccharide component of the Agaricus blazei extract.
[0084] Comparative Example 3
[0085] The polysaccharide was prepared from honeysuckle by the following process: (1) crushing the raw material of honeysuckle and passing it through a 45-mesh sieve for later use; (2) adding deionized water with a solid-liquid ratio of 1:15 (g / mL) to the raw material powder, and soaking for 30 minutes; (3) extracting the material in step (2) at 80°C for 3 hours, filtering with a 300-mesh filter cloth, and collecting the filtrate; (4) concentrating the filtrate in step (3) at 70°C to a viscous state, adding 4 times the volume of anhydrous ethanol according to the volume of the viscous liquid, and allowing the alcohol precipitation to stand for 12 hours, filtering and collecting the polysaccharide precipitate, and obtaining the polysaccharide component of the honeysuckle extract.
[0086] Comparative Example 4
[0087] Polysaccharide was prepared from polygonatum by the following process: (1) the raw material of polygonatum was crushed and passed through a 45-mesh sieve for later use; (2) the raw material powder was added into deionized water with a solid-liquid ratio of 1:15 (g / mL), and soaked for 30 minutes; (3) the material of step (2) was extracted at 80°C for 3 hours, filtered through a 300-mesh filter cloth, and the filtrate was collected; (4) the filtrate of step (3) was concentrated at 70°C to a viscous state, 4 times the volume of anhydrous ethanol was added according to the volume of the viscous liquid, and the alcohol precipitation was allowed to stand for 12 hours, and the polysaccharide precipitate was collected by filtration to obtain the polysaccharide component of the polygonatum extract.
[0088] Comparative Example 5
[0089] The polysaccharide is prepared from red algae by the following process: (1) the red algae raw material is crushed and passed through a 45-mesh sieve for later use; (2) the raw material powder is added into deionized water with a solid-liquid ratio of 1:15 (g / mL), and soaked for 30 minutes; (3) the material of step (2) is extracted at 80°C for 3 hours, filtered through a 300-mesh filter cloth, and the filtrate is collected; (4) the filtrate of step (3) is concentrated at 70°C to a viscous state, 4 times the volume of anhydrous ethanol is added according to the volume of the viscous liquid, and the alcohol precipitation is allowed to stand for 12 hours, and the polysaccharide precipitate is filtered and collected to obtain the polysaccharide component of the red algae extract.
[0090] Example 6 Molecular Weight Determination
[0091] Accurately measure 10 mL of the polysaccharide extract sample prepared in Example 1 and place it in a 50 mL centrifuge tube, add 40 mL of 60% ethanol, mix well, and place it in a 4°C refrigerator for more than 2 hours. Centrifuge it at 4000 r / min for 5 minutes, discard the supernatant, take out the polysaccharide extract, evenly place it in a watch dish, and dry it in a 60°C drying oven for 4-6 hours until the sample is completely dry.
[0092] Accurately weigh 10 mg of the dried sample and place it in a 1.5 mL centrifuge tube. Add 2 mL of 0.1 mol / L sodium nitrate solution and mix well. Place the difficult-to-dissolve sample in 60°C hot water to accelerate dissolution. After complete dissolution, centrifuge at 12000 r / min for 10 min to obtain the sample to be tested.
[0093] Take appropriate amount of 1000, 5000, 12000, 80000, 150000, 270000, 670000, 2000000 molecular weight dextran, accurately weigh, and prepare a mixed standard solution of 4-5 mg / mL. Use TSKgel G4000PWxl column (7.8mm ID×30cm, 10μm), 0.1mol / L sodium nitrate buffer as mobile phase, flow rate 0.5ml / min, and perform isocratic elution at 35℃.
[0094] The results are as follows Figure 1And as shown in Table 1.
[0095] Table 1 Molecular weight distribution of the composite polysaccharide prepared in Example 1
[0096]
[0097]
[0098] pass Figure 1 As can be seen from Table 1, the molecular weight distribution of the composite polysaccharide obtained in Example 1 is 0.5-2432 KDa, and the weight average molecular weight is 321 KDa.
[0099] Example 7 Monosaccharide composition determination
[0100] Accurately measure 10 mL of the polysaccharide extract sample prepared in Example 1 and place it in a 50 mL centrifuge tube, add 40 mL of 60% ethanol, mix well, and place it in a 4°C refrigerator for more than 2 hours. Centrifuge it at 4000 r / min for 5 minutes, discard the supernatant, take out the polysaccharide extract, evenly place it in a watch dish, and dry it in a 60°C drying oven for 4-6 hours until the sample is completely dry.
[0101] Accurately weigh 0.5 g of the dried sample and place it in a 50 mL hydrolysis tube. Add 5 mL of 4 mol / L trifluoroacetic acid solution, mix well, place in an oven at 110 °C for hydrolysis for 1.5 h, take out and cool, adjust the pH to 7.0 with 4 mol / L sodium hydroxide solution, transfer the solution to a 50 mL volumetric flask, and then make up to volume with deionized water. Store at -20 °C for later use.
[0102] Take appropriate amounts of mannose, lyxose, rhamnose, galacturonic acid, glucose, galactose, xylose, arabinose, fucose, fructose, and glucuronic acid reference substances, accurately weigh them, prepare a 500 mg / L mixed standard solution of mix9 (calculated based on the glucose concentration), and dilute them into a series of standard curve solutions.
[0103] Pipette 400μL of the sample and mixed standard solution into a 5mL stoppered test tube for derivatization. First, add 400μL of 0.5mol / L PMP-methanol solution to the test tube, then add 400μL of 0.3mol / L sodium hydroxide solution, mix well, and react in a 70℃ water bath for 100min. After the reaction, add 500μL of 0.3mol / L hydrochloric acid solution to adjust the pH to neutral, shake well, cool to room temperature, add 1mL of chloroform, vortex evenly, centrifuge at 900rpm for 5min, discard the chloroform layer, collect the supernatant, repeat the above operation 5 times, and finally take the supernatant to pass through a 0.45μm water system membrane, and the filtrate is stored at -20℃ waiting for injection.
[0104] Agilent C18 (4.6 mm × 250 mm, 5 μm) was used for analysis with a detection wavelength of 250 nm and a flow rate of 1.0 ml / min. The elution process used 0.05 mol / L phosphate buffer as mobile phase A and acetonitrile as mobile phase B. The gradient elution was in the following ratios (mobile phase A: mobile phase B): 0 min: 82%: 18%, 27 min: 20%: 80%, 43 min: 82%: 18%.
[0105] The results are shown in Table 2.
[0106] Table 2 Monosaccharide composition of the complex polysaccharide prepared in Example 1
[0107] Mannose Rhamnose Galacturonic acid glucose Galactose Xylose Arabinose Fucose 0.98% 1.36% 0.39% 80.93% 13.14% 0.80% 1.99% 0.41%
[0108] The results showed that the monosaccharide composition included mannose, rhamnose, galacturonic acid, glucose, galactose, xylose, arabinose, and fucose.
[0109] Example 8 Scanning electron microscopy characterization
[0110] A trace amount of composite polysaccharide sample was adhered to a treatment sheet with conductive tape, and after gold spraying treatment, conductivity analysis was performed, and the microscopic morphology of each polysaccharide was observed using an electron microscope. Figure 2 This is a SEM scan of the composite polysaccharide of Example 1. The composite polysaccharide is in a mixed form of crystalline and amorphous states and has a lamellar structure, indicating that the composite polysaccharide prepared in Example 1 has the characteristics of multiple polysaccharide raw materials; the composite polysaccharide has a combination of polysaccharides that have an immunomodulatory effect, and has a more significant effect on regulating Th1 / Th2 immune balance relative to the immunomodulatory effect of a single polysaccharide.
[0111] Example 9 Congo red test
[0112] 5 mol / L NaOH solution was added to a mixture of 2 mL of the complex polysaccharide (1 mg / mL) in Example 1 and 2 mL of Congo red (80 μmol / L) to make the final concentrations of NaOH 0, 0.1, 0.2, 0.3, 0.4 and 0.5 mol / L, respectively, and a UV spectrophotometer was used to scan the wavelength of 400-600 nm at each NaOH concentration, and the maximum absorption wavelength of the mixed solution at each NaOH concentration was recorded. Distilled water was used as a blank control, the NaOH concentration was used as the abscissa, and the maximum absorption wavelength was used as the ordinate to draw a plot.
[0113] There is a close relationship between the triple helical structure of polysaccharides and their immunomodulatory activity. The Congo red test showed that compared with the single plant polysaccharides in Comparative Examples 1-5, the composite polysaccharide showed a more obvious trend of first increasing and then decreasing, indicating that it has a more obvious triple helical conformation and better immunomodulatory activity ( Figure 3 ).
[0114] Effect Example 1 Inhibition of Ovalbumin-induced Immune Stress
[0115] The composite polysaccharide solid powder (hereinafter referred to as composite polysaccharide) prepared according to the raw material ratio and process provided in Example 1 was subjected to efficacy verification experiments. As a comparative experiment of synergistic enhancement, the polysaccharides extracted from single components of Comparative Examples 1-5 were set for comparison.
[0116] Experimental method: Reference literature method (Yang Ling, Liu Jie, Li Jiangping, Li He. Study on the role of ephedrine-mediated TSLP / OX40L pathway in regulating Th2 immune response in rats with allergic rhinitis [J]. Chinese Journal of Immunology, 2022, 38(03): 319-323.), ovalbumin (OVA) modeling was used, SD rats were used as modeling animals, and 54 SD rats were randomly divided into 9 groups, 6 rats / group, namely blank group, model group, positive group (loratadine), Example 1 group, and single polysaccharide group (Comparative Examples 1-5, a total of 5 groups).
[0117] Except for the blank group, the other experimental groups were intraperitoneally injected with OVA solution (0.3 mg ovalbumin (OVA), 30 mg Al(OH)3 mixed in 1 mL saline) on days 1, 3, 5, 7, 9, 11, and 13 to strengthen sensitization. Starting from the 15th day, SD rats were challenged with OVA nasally. Except for the blank group, 50 μL OVA (0.1 mg / μL) was dripped into the nostrils of each group of SD rats for continuous stimulation for 7 days. On the 21st day (after the last nasal drop), the degree of sneezing, scratching and runny nose symptoms was counted, and the scoring criteria were statistically analyzed according to Table 3 for behavioral index results; samples were collected 24 hours after stimulation on the 21st day. The levels of IL-13, IL-31, IgE, and HIS (histamine) in rat serum were detected.
[0118] Table 3 Scoring criteria for nasal symptoms in rats with allergic rhinitis
[0119] symptom Mild (1 point) Moderate (2 points) Severe (3 points) Nose scratching frequency times / 30 minutes 1~3 4~10 >10 Number of sneezes / 30 minutes 1~4 5~10 >10 Runny nose / minute Flow to the anterior nostril Drainage from anterior nares Tears streaming down one's face
[0120] The animal experiment was administered by gavage for 21 days, starting from the establishment of the model, and the specific settings were as follows: (1) blank control group and model group were given 0.9% NaCl saline; (2) Example 1 group, complex polysaccharide (dose of 200 mg / kg / d, solvent of 0.9% NaCl saline); (3) positive group, loratadine (dose of 2 mg / kg / d, solvent of 0.9% NaCl saline); (4) single polysaccharide group (comparative examples 1-5, a total of 5 groups, dose of 200 mg / kg / d, solvent of 0.9% NaCl saline), respectively extracted and prepared according to the processes of comparative examples 1-5.
[0121] In the OVA model experiment, by monitoring the IL-13 and IL-31 indicators, it can be found that after modeling, IL-13 and IL-31 were upregulated to a certain extent, but after the administration of the polysaccharides of Comparative Examples 1-5 and Example 1, these two indicators decreased, among which the composite polysaccharide of Example 1 decreased most significantly ( Figure 4 and Table 4).
[0122] Table 4 Expression levels of IL-13, IL-31, IgE and HIS in mouse serum
[0123] Group IL-13 (pg / mL) IL-31 (pg / mL) IgE (μg / mL) HIS (ng / mL) Blank Group <![CDATA[28.76±0.54 * ]]> <![CDATA[44.64±1.26 * ]]> <![CDATA[1.98±0.12 * ]]> <![CDATA[14.15±0.26 * ]]> Model Group 36.87±2.07 58.85±4.90 3.16±0.52 17.11±0.49 Positive group <![CDATA[32.21±1.47 * ]]> <![CDATA[48.65±3.14 * ]]> 2.49±0.15 <![CDATA[14.60±0.45 * ]]> Comparative Example 1 <![CDATA[36.00±0.56 # ]]> <![CDATA[56.73±2.54 # ]]> 2.85±0.22 <![CDATA[15.65±0.40 *# ]]> Comparative Example 2 <![CDATA[35.58±0.63 # ]]> <![CDATA[55.35±0.82 # ]]> 2.82±0.53 <![CDATA[15.20±0.16 * ]]> Comparative Example 3 <![CDATA[35.42±0.70 # ]]> <![CDATA[58.03±0.93 # ]]> <![CDATA[3.26±0.15 # ]]> <![CDATA[16.84±0.45 # ]]> Comparative Example 4 <![CDATA[35.09±1.53 # ]]> <![CDATA[57.73±1.65 # ]]> 2.93±0.60 <![CDATA[15.35±0.31 *# ]]> Comparative Example 5 <![CDATA[37.22±1.67 # ]]> <![CDATA[54.98±0.71 # ]]> 2.64±0.55 <![CDATA[14.99±1.22 * ]]> Example 1 <![CDATA[30.99±0.98 * ]]> <![CDATA[50.56±2.02 * ]]> <![CDATA[2.27±0.19 * ]]> <![CDATA[14.26±0.67 * ]]>
[0124] Note: Compared with the model group, *P<0.05; compared with the Example 1 group, #p<0.05.
[0125] Figure 5 is the relative expression of IgE and HIS in each group in serum, combined with Table 4, Figure 5 It can be seen that the Example 1 group can effectively reduce the expression of IgE and HIS factors in the serum of rats in the state of sexual immune stress, and has the function of synchronously regulating multiple immune factors to achieve a synergistic purpose. The effect is close to that of positive drugs. The effect of the composite polysaccharide of Example 1 is better than any group of Comparative Examples 1-5.
[0126] Table 5 shows the behavioral index results of each experimental group; as shown in Table 5, in the OVA model animal experiment, compared with the blank control group, the model group had increased symptoms of sneezing, scratching the nose and runny nose, and compared with the model group, these symptoms of the rats in Example 1 group were alleviated, which was better than any of the comparative examples 1-5 and the positive group.
[0127] Table 5 Behavioral index results of each experimental group (mean)
[0128] Experimental Group Nose scratching score Sneeze score Runny nose score Total score Blank Group 0.17 0.17 0 0.33 Model Group 1.67 2.00 1.67 5.00 Positive group 0.50 0.50 0.33 1.33 Comparative Example 1 1.40 1.00 1.00 3.20 Comparative Example 2 0.67 0.50 0.33 1.50 Comparative Example 3 0.83 0.50 0.33 1.67 Comparative Example 4 0.67 0.50 0.33 1.50 Comparative Example 5 1.00 0.50 0.25 1.75 Example 1 0.50 0.25 0.25 1.00
[0129] Figure 6 This is a comparison of the effects of this experiment on anti-OVA-induced allergic rhinitis. From the perspective of runny nose and redness and swelling, it can be found that the composite polysaccharide is significantly better than any group of comparative examples 1-5 in terms of anti-OVA-induced allergic rhinitis, and has obvious synergistic effects (characteristics of the red circle part).
[0130] Obviously, under the condition of equal dosage, the inhibitory effect of the composite polysaccharide on IL-13, IL-31, IgE and HIS is better than any other control group. According to the calculation method of the synergistic index (Berenbaum M C. The expected effect of a combination of agents: the general solution. Journal of Theoretical
[0131] Biology, 1985, 114: 413-431.)
[0132]
[0133] Where Xi: the dosage of the ith drug in combination therapy; Xie: the dosage of the ith drug that can produce the same effect as the combination therapy when used alone; n: the number of drugs in combination therapy; when the Berenbaum index is less than 1, it indicates a synergistic effect.
[0134] According to the mass percentage of the Chinese herbal medicine used in Example 1, the calculated Berenbaum index should be:
[0135]
[0136] Among them, "200" is the dosage of the compound polysaccharide (mg / kg / d), and the other percentages represent the proportions of different single drugs in the compound polysaccharide. 1e , X 2e , X 3e , X 4e , X 5e The dosages (mg / kg / d) of Agaricus blazei, red algae, Glycyrrhiza glabra, Polygonatum sibiricum, and Flos Lonicerae can produce the same effect as the combination when applied alone. Obviously, when their values are "200", the Berenbaum index is equal to 1. According to the scheme of Experiment 1, Example 1 and Comparative Examples 1-5 were tested at a dosage of 200 mg / kg / d. The regulatory effects of Example 1 on IL-13, IL-31, IgE, and HIS induced by the model were better than those of single administration, that is, X in the formula is 1e , X 2e , X 3e , X 4e , X 5eThe actual values are all greater than 200, and it can be estimated that the Berenbaum index of the composite polysaccharide of Example 1 is less than 1 under the OVA model, that is, it has a synergistic effect. IL-13 and IL-31 are involved in the Th2 immune process. Therefore, the composite polysaccharide of Example 1 can regulate the Th1 / Th2 immune balance, downregulate the expression of IgE and HIS, thereby alleviating the development of OVA-induced allergic rhinitis symptoms, and has a significant synergistic effect.
[0137] The above specific implementations have been described in detail for the present invention, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.
Claims
1. A polysaccharide composition, comprising a polysaccharide extract of a raw material drug, wherein the raw material drug comprises the following components in percentage by mass: 20%-40% Agaricus blazei, 10%-30% seaweed, 5%-25% liquorice, 5%-25% polygonatum, and 5%-20% honeysuckle.
2. The polysaccharide composition according to claim 1, characterized in that The raw material medicine comprises the following components in percentage by mass: 30%-40% of Agaricus blazei, 10%-20% of seaweed, 10%-25% of liquorice, 15%-25% of polygonatum, and 5%-15% of honeysuckle.
3. The polysaccharide composition according to any one of claims 1 to 2, characterized in that The seaweed is at least one of brown algae, red algae, kelp and wakame; and / or the licorice is at least one of uralensis, licorice inflated fruit and licorice glabra.
4. The method for preparing the polysaccharide composition according to any one of claims 1 to 3, comprising the following steps: The raw materials are crushed and mixed, soaked in water for extraction, the filtrate is collected and concentrated, and the precipitate is collected by alcohol precipitation.
5. The preparation method according to claim 4, characterized in that: The extraction conditions are: temperature 70-90° C., time 2-4 h; and / or, the alcohol precipitation is adding 3-5 times the volume of anhydrous ethanol for 10-14 h.
6. Use of the polysaccharide composition according to any one of claims 1 to 3 in any of the following: (1) Preparation of products for regulating Th1 / Th2 balance; (2) preparing products for preventing and / or treating diseases related to Th1 / Th2 imbalance; (3) Application in the preparation of products for improving immunity; The Th1 / Th2 imbalance-related diseases include allergies and / or allergy-related diseases.
7. The use according to claim 6, characterized in that: The allergy-related diseases include allergic rhinitis and allergic asthma.
8. The use according to claim 7, characterized in that: The allergies include those caused by ovalbumin.
9. The use according to claim 6, characterized in that: The product includes at least one of food, medicine and health care product.
10. A product comprising the polysaccharide composition according to any one of claims 1 to 3.
Citation Information
Patent Citations
Polysaccharide with antitumor and immunologic adjuvant function as well as preparation method and purpose thereof
CN101518556A
Formula and preparation technology of polysaccharide body capable of strengthening immunity of human bodies
CN109463742A
